Eli Lilly and Novo Nordisk

Inspire Medical Systems Cuts Outlook After V Rollout Setbacks Trigger Stock Slide

Slow U.S. onboarding of the Inspire V system—coupled with surging GLP-1 therapy adoption—drove the full-year guidance cut, sending shares tumbling over 30%.